The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation

Eva Sum(Roche (Switzerland)), Pablo Umaña(Zurich Insurance Group (Switzerland))

Journal for ImmunoTherapy of Cancer

March 1, 2022

10.1136/jitc-2021-003264

Cited by 24

Related Papers

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

|Nature|2022|257

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity

|Clinical Cancer Research|2021|62

Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1

|Research Square|2021|5